CN Patent
CN109125325B — 前列环素受体激动剂的医药用途
Assigned to Chinese PLA General Hospital · Expires 2021-05-25 · 5y expired
What this patent protects
本发明提供了一种符合通式I所示的化合物、其异构体或其药学上可接受的盐在制备治疗和/或高原病的药物组合物中的用途,所述的高原病选自在海拔2000m以上的高原环境下产生的急性高原病或慢性高原病。
USPTO Abstract
本发明提供了一种符合通式I所示的化合物、其异构体或其药学上可接受的盐在制备治疗和/或高原病的药物组合物中的用途,所述的高原病选自在海拔2000m以上的高原环境下产生的急性高原病或慢性高原病。
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.